Molecular pathways: Fumarate Hydratase-deficient kidney cancer - Targeting the warburg effect in cancer

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3345-3352

  Linehan, W Marston ^a   Rouault, Tracey A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; BEVACIZUMAB; BORTEZOMIB; CISPLATIN; ENGLERIN A; ERLOTINIB; FATTY ACID; FUMARATE HYDRATASE; FUMARIC ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; HEME OXYGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRON; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTATE DEHYDROGENASE; METFORMIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SESQUITERPENE DERIVATIVE; TRANSCRIPTION FACTOR NRF2; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR;

AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANTIOXIDANT ACTIVITY; CELL LEVEL; CELL PROLIFERATION; CITRIC ACID CYCLE; DRUG RESEARCH; DRUG TARGETING; ENZYME DEFICIENCY; ENZYME INACTIVATION; FATTY ACID SYNTHESIS; FH GENE; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE MUTATION; GERM LINE; GLUCOSE TRANSPORT; HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA; HUMAN; INHIBITION KINETICS; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MISSENSE MUTATION; NEPHRECTOMY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; DEFICIENCY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; SKIN NEOPLASMS; TRANSLATIONAL RESEARCH; UTERINE NEOPLASMS;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; FUMARATE HYDRATASE; HUMANS; LEIOMYOMATOSIS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; UTERINE NEOPLASMS;

EID: 84879875481     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0304     Document Type: Review

References (55)

1. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001;98:3387-2.
2. Zbar B, Glenn GM, Lubensky IA, Choyke P, Magnusson G, Bergerheim U, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995;153:907-12.
3. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006;43:18-27. (Pubitemid 43099991)
4. Rothman A, Glenn GM, Choyke L, Srinivasan R, Linehan WM, Cowen EW. Multiple painful cutaneous nodules and renal mass. J Am Acad Dermatol 2006;55:683-6. (Pubitemid 44467993)
5. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106. (Pubitemid 36793783)
6. Schmidt LS, Duh FM, Chen F, Kishida T, Glenn GM, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73. (Pubitemid 27198158)
7. Schmidt LS, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50. (Pubitemid 29192711)
8. Merino MJ, Torres-Cabala C, Pinto PA, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007;31:1578-85. (Pubitemid 47482473)
9. Grubb RL III, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007;177:2074-80. (Pubitemid 46735952)
10. Herring JC, Enquist EG, Chernoff A, Linehan WM, Choyke PL, Walther MM. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001;165:777-81. (Pubitemid 32156275)
11. Pavlovich CP, Grubb RL, Hurley K, Glenn GM,Toro J, Schmidt LS, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dubé Syndrome. J Urol 2005;173:1482-6. (Pubitemid 40524753)
12. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
13. Kiuru M, Launonen V, Hietala M, Aittomaki K, Vierimaa O, Salovaara R, et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001;159:825-9. (Pubitemid 32847173)
14. Lehtonen R, Kiuru M, Vanharanta S, Sjoberg J, Aaltonen LM, Aittomaki K, et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 2004;164:17-22. (Pubitemid 38364585)
15. Sanz-Ortega J, Vocke C, Stratton P, Linehan WM, Merino MJ. Mophologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013;37:74-80.
16. Yang Y, Valera VA, Padilla-Nash HM, Sourbier C, Vocke CD, Vira MA, et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010;196:45-55.
17. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011;20:315-27.
18. Yang Y, Valera V, Sourbier C, Vocke CD, Wei M, Pike L, et al. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet 2012;205:377-90.
19. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8. (Pubitemid 32335941)
20. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-53. (Pubitemid 41132743)
21. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011;25:1895-908.
22. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40. (Pubitemid 33063099)
23. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 2007;14:420-6. (Pubitemid 46685876)
24. Ghosh MC, Zhang D, Jeong SY, Kovtunovych G, Ollivierre-Wilson H, Noguchi A, et al. IRP1 deletion causes polycythemia and pulmonary hypertension in mice through translational de-repression of HIF2a. Cell Metab 2013;17:271-81.
25. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-55. (Pubitemid 41039149)
26. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46. (Pubitemid 41039148)
27. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, et al. Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene. Cancer Discov 2011;1:222-35.
28. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85.
29. LumJJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007;21:1037-49. (Pubitemid 46686473)
30. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21:297-308.
31. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2011;481:385-8.
32. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011;20:524-37.
33. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An Antioxidant Response Phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011;20:511-23.
34. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 2012;148:1132-44.
35. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 2011;10:37.
36. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
37. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005;25:162-71. (Pubitemid 40039808)
38. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-9. (Pubitemid 41418022)
39. Rachakonda G, Xiong Y, Sekhar KR, Stamer SL, Liebler DC, Freeman ML. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem Res Toxicol 2008;21:705-10. (Pubitemid 351498046)
40. Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244:21-6.
41. Alderson NL, Wang Y, Blatnik M, Frizzell N, Walla MD, Lyons TJ, et al. S-(2-Succinyl) cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys 2006;450:1-8. (Pubitemid 43782733)
42. Nagai R, Brock JW, Blatnik M, Baatz JE, Bethard J, Walla MD, et al. Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress. J Biol Chem 2007;282:34219-28. (Pubitemid 350159439)
43. Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 2011;225:4-11.
44. Sudarshan S, Sourbier C, Kong HS, Block K, Romero VV, Yang Y, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1 alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009;15:4080-90.
45. Sourbier C, Valera-Romero V, Giubellino A, Yang Y, Sudarshan S, Neckers L, et al. Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. Cell Cycle 2010;9:4183-9.
46. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011;477:225- 8.
47. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med 2012;209:211-5.
48. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009;8:626-35.
49. Ratnayake R, Covell D, Ransom TT, Gustafson KR, Beutler JA. Englerin A, a selective inhibitor of renal cancer cell growth, from Phyllanthus engleri. Org Lett 2009;11:57-60.
50. Akee RK, Ransom T, Ratnayake R, McMahon JB, Beutler JA. Chlorinated englerins with selective inhibition of renal cancer cell growth. J Nat Prod 2012;75:459-63.
51. Sulzmaier FJ, Li Z, Nakashige ML, Fash DM, Chain WJ, Ramos JW. Englerin a selectively induces necrosis in human renal cancer cells. PLoS ONE 2012;7:e48032.
52. Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee M-J, et al. Englerin A stimulates PKCu to inhibit insulin signaling and simultaneously activate HSF1: An example of pharmacologically induced synthetic lethality. Cancer Cell 2013;23:228-37.
53. NIH (2010) A phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell carcinoma. Available from: http://clinicaltrials.gov/show/NCT01130519.
54. Bayley JP, Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev 2010;20:324-9.
55. Koivunen P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007;282:4524-32. (Pubitemid 47100953)